Celldex Therapeutics stock
CLDXNASDAQCelldex Therapeutics, Inc., HealthcareISIN US15117B2025
36Score 36 out of 100, Weak
Price and trend
49 / 100
Price history
+18% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 13% below it.
Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 47).
The price is 36% below its 52-week high. Largest decline in 20 years: 100% (October 2013 to March 2020).
Chart figures for advanced users
- SMA 50$32.19
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$32.82
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)47
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$22.58
- The lowest closing price of the last twelve months.
- Resistance$44.87
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Celldex Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $2.24B, is number 116 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.5M (down 78.6% year on year) and a loss of $258.8M.
- MEQIRI Score 36 out of 100 (Weak): rank 614 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $650.32M, financial debt $9.87M.Stability 74
Weaknesses
- DilutionShare count up 124% since 2020.Capital allocation 18
- Revenue shrinkingRevenue down 27.4% a year since 2020.Growth 32
- Loss-makingLoss of $309.11M over the last 12 months.Fundamentals 17
Its standout strength is stability, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 78.6% on the prior year. Revenue has declined since 2011 (-12% per year), so it is worth watching closely. From 2011 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −19160%, net −17253%. Last 12 months: net −100%. From 2011 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 5 Nov 2026EPS reported −$0.96 (expected −$1.02)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$4.130.0%
- Revenue
- $1.7M0.0%
- Earnings per share
- −$4.23−0.3%
- Revenue
- $8.76M−12.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Celldex Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 36
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- NewAmsterdam PharmaNAMS $2.48B35
- Zealand PharmaZEAL.CO $2.42B59
- PharvarisPHVS $2.4B44
- Palvella TherapeuticsPVLA $2.4B43
- Trevi TherapeuticsTRVI $2.37B41
- BiohavenBHVN $2.29B43
- Replimune GroupREPL $2.29B43
- SepternaSEPN $2.27B48
ETFs that hold Celldex Therapeutics
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.11% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.08% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.08% | 0.30% | €4.22B |
Show 5 more
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.07% | 0.35% | €434.1M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.06% | 0.43% | €2.48B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.02% | 0.35% | €8.19B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €944.34M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.01% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2006)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.